68 filings
Page 2 of 4
8-K
natkvn
3 Jan 23
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors
8:45am
8-K
28r1gdpezape
14 Dec 22
Other Events
4:00pm
8-K
09q182564c1nrz
1 Dec 22
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
5:19pm
8-K
uiw gs447
28 Nov 22
CNS Pharmaceuticals Announces Reverse Stock Split
5:13pm
8-K
udqjkpg
24 Oct 22
Other Events
5:15pm
8-K
dkk07z52epy yp
26 Aug 22
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
xk0hj
19 Aug 22
Other Events
8:01am
8-K
zy4c7rr7fzb3z0fnr
16 Aug 22
Other Events
4:02pm
8-K
b5itr 9mrcyaxgumkx8
15 Aug 22
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
9:09am
8-K
8pl68t0
4 Aug 22
Other Events
5:02pm
8-K
s5gvc 9iuexw4m4ra
28 Jul 22
Other Events
4:02pm
8-K
1pfd mm00a
16 May 22
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:38pm
8-K
z5v8l1i1jcz
3 Mar 22
CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
8:40am
8-K
ua5b4 df44o6fmgcgr
18 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:04pm
8-K
7b7 txcsks
10 Jan 22
Regulation FD Disclosure
9:25am
8-K
rm3 ly6ugz
6 Jan 22
CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
9:11am
8-K
awumxbohc205qar4j
3 Dec 21
Regulation FD Disclosure
4:08pm
8-K
zxwodd60p3g 9k
13 Aug 21
CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook
8:10am
8-K
3xpmyjiv3ghsiuu2
19 Jul 21
Regulation FD Disclosure
7:48am
8-K
8i0xv
1 Jul 21
Submission of Matters to a Vote of Security Holders
9:04am